Mark joined PacBio as Chief Operating Officer where he manages our research, development, and manufacturing organizations and is responsible for driving our strategic planning and corporate development activities. Mark joined the company from Illumina, Inc. where he most recently served as Senior Vice President and Chief Commercial Officer. In that role, he was responsible for the development and implementation of lllumina’s commercial strategy and oversaw worldwide sales and services of over $3B in annual revenue and ~1,800 commercial employees. Prior to Illumina, Mark was the Director of Genotyping Services for Ellipsis Biotherapeutics. He earned as BS in Biochemistry from Western University and was a PhD candidate at the University of Toronto in the department of Molecular and Medical Genetics. During that time, his research was focused on Cystic Fibrosis at the Hospital for Sick Children in Toronto.
Genomic Profiling Showcase:
PacBio Systems are powered by Single Molecule, Real-Time Sequencing and provide comprehensive views of genomes, transcriptomes, and epigenomes. As the only sequencing technology to offer highly accurate long reads (HiFi reads), PacBio provides unparalleled access to the full spectrum of genetic variation in any organism
PacBio for the Future
PacBio for the Future
Session Abstract – PMWC 2023 Silicon Valley
The PMWC 2023 Genomic Profiling Showcase will provide a 15 min speaking opportunity for selected companies working with the latest technologies in nucleic acid sequencing such as NGS, providing instrumentation for genomic sequencing, and offering direct to consumer services. These companies will share their innovative products and services to an audience of leading investors, potential clients and partners. The Genomic Profiling Showcase will exhibit the latest innovations in methods and instruments used for DNA/ RNA sequencing to ascertain the genomic and transcriptional profile of a person in order to understand why some people get certain diseases while others do not, or why people react in different ways to the same drug. This information is also being used to develop new ways to diagnose, treat, and prevent diseases, such as cancer.